Survival analysis by tumor type revealed that EGFR amplifications in low-grade gliomas and head and neck cancers, CCNE1 amplifications in ovarian and uterine cancers, and CDK4 amplifications in sarcomas were associated with a low probability of OS, suggesting that only certain amplifications in particular tumor types are relevant in prognosis (Supplementary Figure S2e–t). Here, CDK4 is linked to glioma.